Topic:

Clinical Trials

Latest Headlines

Latest Headlines

Following a setback, Pfizer gets a win in Phase III cancer drug study

Two years after going down in flames in a Phase III study for CD22-positive non-Hodgkin's lymphoma, Pfizer has helped resurrect hopes for top drug prospect inotuzumab ozogamicin, saying the drug hit its first primary endpoint for spurring hematologic remission in patients with CD22-positive acute lymphoblastic leukemia.

Ampio routed as lead osteoarthritis drug flunks a PhIII test

Shares of Ampio Pharmaceuticals were crushed this morning after the biotech acknowledged that its lead drug flunked a Phase III test for osteoarthritis. And the news comes just days after one of its drug subsidiaries was absorbed into a new biotech that will be called Aytu.

Actelion launches Phase III MS test for ponesimod

Buoyed by the success of its PAH franchise, Switzerland's Actelion says it has begun a Phase III study of its in-house drug ponesimod for multiple sclerosis.

Targacept tanks (again) after its last surviving drug program flops

The litany of clinical trial disasters that has played out at Targacept over the past three years continues this morning with the news that its last remaining pipeline asset failed a Phase I/II study for diabetic gastroparesis. And as has happened so many times before, the biotech's share price took another nasty tumble, dropping 22%.

Pharmalink wraps up PhIIb trial early after interim efficacy data impresses

Pharmalink has stopped a Phase IIb trial of its primary IgA nephropathy treatment early after it met its primary endpoint in a planned interim analysis. The success makes Pharmalink a rare example of a private biotech with an unpartnered, Phase III-ready asset, characteristics that inevitably lead to talk of IPOs and deals.

The flimsy case for a miracle ALS drug collapses under expert scrutiny

Given the varying ways that individual ALS patients progress, gradually growing paralyzed and dying in 3 to 5 years, he reasoned, the results from 8 patients after only 12 weeks of treatment, with 4 patients reserved for the placebo arm, couldn't provide a reliable look at efficacy.

Pfizer's palbociclib impresses in PhIII breast cancer study

Pfizer reported today that it had cut short a Phase III study of palbociclib, recently approved under an accelerated pathway as Ibrance, after clearly demonstrating that it had met its primary endpoint: progression-free survival with a combination of Ibrance plus fulvestrant in women with hormone receptor positive, human epidermal growth factor receptor 2 negative metastatic breast cancer.

Galapagos' closely watched rheumatoid arthritis drug filgotinib scores in PhIIb

Belgium's Galapagos says that its oral JAK1 inhibitor filgotinib met its primary and other endpoints in a crucial Phase IIb study for rheumatoid arthritis.

Roche hustles its PD-L1 'breakthrough' star into 11 late-stage trials

In the checkpoint receptors race, Bristol-Myers Squibb is out in front with the biggest and fastest effort, a comeback Merck is in hot pursuit and Roche/Genentech and AstraZeneca are following but still in the front of the pack.

AstraZeneca's MedImmune gets RSV candidate fast-tracked

Two Maryland-based companies are racing to get a vaccine for respiratory syncytial virus to market--and one just picked up a regulatory boost.